Biogen

Aging Demographics And Genetic Advances Will Unlock Neurological Breakthroughs

AnalystHighTarget

Not Invested

Community Contributor

Published

11 Apr 25

Updated

07 May 25

n/a

AnalystHighTarget's Fair Value

n/a

11.0%

4.6%

11.0%

4.6%

You can edit this narrative until May 12 6:00 AM. Then, changes will post as Updates.

Author's Valuation

US$247.8829.3% undervalued

AnalystHighTarget Fair Value

Narrative

Updates4

Shared on 07 May 25

Fair value Decreased 13%

Shared on 30 Apr 25

Fair value Decreased 6.36%

AnalystHighTarget has decreased revenue growth from 1.5% to 0.8%.

Shared on 23 Apr 25

Fair value Increased 20%

AnalystHighTarget has increased future PE multiple from 15.0x to 18.0x.

Shared on 16 Apr 25

Fair value Decreased 0.091%

AnalystHighTarget has increased revenue growth from 0.8% to 1.5%.

AnalystHighTarget Fair Value

US$247.88

29.3% undervalued

Future estimation in

% p.a.

Decrease

Increase

Current revenue growth rate

-1.79%

Biotech revenue growth rate

8.57%

Risk Level (Discount Rate)

Our default considers factors like the company's size, volatility, profitablity and country of operation.

Decrease

Increase

Current discount rate

7.44%

Calculation

US$3.29b

Earnings '28

13.82x

PE Ratio '28

US$45.48b

Market Cap '28

US$45.48b

Market Cap '28

149.33m

No. shares '28

US$304.56

Share Price '28

US$304.56 Share Price '28

Discounted to 2025 @ 7.19% p.a.

US$247.32

Fair Value '25